On September 24, 2026, the U.S. Court of Appeals for the Seventh Circuit heard oral argument in Eli Lilly and Company v. Kennedy, No. 26-1301. The case is Lilly's challenge to the Food and Drug Administration's decision that retatrutide, its investigational triple agonist for obesity, is not a protein and therefore not a biological product.
The panel was Chief Judge Michael B. Brennan and Circuit Judges Frank H. Easterbrook and Thomas L. Kirsch II. It took the case under advisement, but not before raising a question neither side's briefs had fully addressed: whether the court has jurisdiction to hear the appeal at all. The same day, it ordered both parties to file supplemental memoranda on that question by October 8, 2026.
Why the label matters
A drug and a biological product reach the U.S. market through different statutes. Drugs are approved under the Federal Food, Drug, and Cosmetic Act and a new chemical entity generally receives five years of exclusivity. Biological products are licensed under the Public Health Service Act, and a biosimilar cannot be approved until 12 years after the reference product was first licensed. Copies of a drug arrive as generics through an abbreviated new drug application, while copies of a biologic arrive as biosimilars. FDA's own brief in this appeal describes the exclusivity difference as "substantially longer" for biologics.
Congress lists "protein" among the categories of biological product but never defined the word. FDA did, in a 2020 rule: a protein is "any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size." Anything at or under that line, such as semaglutide or tirzepatide, is regulated as a drug. That line also decides which peptides can be copied through the generic-drug pathway covered in our post on FDA's July 2026 peptide guidances.
The 41st amino acid
By Lilly's own description, retatrutide has a backbone of 39 alpha amino acids and a second, attached chain of two more: one gamma-glutamate and one 8-amino-3,6-dioxaoctanoic acid (ADO), joined to a lysine in the backbone. That makes 41 amino acids in total. FDA counted at most 40 alpha amino acids, because ADO is not one. An alpha amino acid has a single carbon between its amino and carboxyl groups. ADO has a longer chain of carbons and oxygens between them.
So the whole dispute turns on one word. The definition says "alpha" at the start ("alpha amino acid polymer") but not in the size requirement ("greater than 40 amino acids"). Lilly reads that omission as deliberate, which would count all 41. FDA reads "alpha" as carrying through the sentence, which stops the count at 40.
FDA's brief adds a pointed detail. Lilly's own 2023 label for Mounjaro described tirzepatide, which has a 39-residue backbone and a similar side chain, as a "39-amino-acid" peptide. FDA also quotes a 2014 Lilly comment to the agency defining a protein as a linear polymer of alpha amino acids.
How the case got here
- November 2023: Lilly asks FDA to designate retatrutide a biological product. FDA asks for more information and Lilly resubmits in January 2024.
- March 18, 2024: FDA classifies retatrutide as a drug, finding it neither a protein nor analogous to one.
- September 3, 2024: Lilly sues in the Southern District of Indiana.
- September 30, 2025: Judge Tanya Walton Pratt upholds FDA on the protein question, but sets aside its finding that retatrutide is not "analogous" to a protein and sends that question back to the agency.
- December 16, 2025: final judgment enters.
- February 12, 2026: Lilly appeals.
"Analogous product" is a separate category in the statute, and FDA has never defined it by rule. The district court held that FDA cannot require an analogous product to meet every element of the protein definition, because that would read the category out of the statute. It added that there is a "meaningful possibility" FDA could lawfully reach the same result on remand. That remand is still open.
The argument: jurisdiction first
Less than a minute into Lilly's argument, the bench turned to appellate jurisdiction. The general rule is that a district court order sending a case back to an agency is not a final decision and cannot be appealed yet. Lilly relied on a Seventh Circuit exception from Rush University Medical Center v. Leavitt (2008).
One judge said, "I must say, I am very skeptical of this." The judge noted that the jurisdictional section of Lilly's brief cited no Supreme Court decision, and said that using a Seventh Circuit decision to override what the Supreme Court has called the canonical rule against appealing remands was, "well, insubordination is one possible word." The judge also named the underlying concern: if Lilly wins on the analogous-product question back at FDA, a ruling on what "alpha" modifies would be an advisory opinion.
Steven H. Hazel, arguing for the government, said FDA agreed the court had jurisdiction under Rush. Asked whether the government had checked its broader position with the Solicitor General, Hazel said it had not, and acknowledged that the D.C. Circuit would not allow an appeal like this one. The written order that followed asks the parties to cover how the Seventh Circuit, the Supreme Court and the other courts of appeals have treated appeals by private parties from remands to agencies.
The argument: what "alpha" modifies
Allon Kedem, arguing for Lilly, said FDA wrote "alpha" once and then left it out of both the size requirement and the counting instruction that follows, and that courts presume such omissions are deliberate. Kedem pointed to Congress's 2019 removal of the statutory exclusion for chemically synthesized polypeptides, arguing that the textbooks FDA relies on describe proteins made by living cells, not by synthesis, and said FDA could have written "greater than 40 alpha amino acids" if that is what it meant.
Hazel argued that scientists understand a protein as a chain of alpha amino acids, because only alpha amino acids form the peptide bonds that make a protein's backbone, and that the 2020 rule's preamble says so. Dropping "alpha" after first use, Hazel said, is ordinary shorthand in both FDA's rulemaking and the scientific literature. Lilly's reading, the government argued, leaves no clear threshold: it does not say how many alpha amino acids an "alpha amino acid polymer" needs.
The bench pressed that premise. One judge questioned an argument that runs from what scientists think to what the regulation means: "Regulations aren't addressed to scientists. They're mostly addressed to lawyers." The question of who the regulation's audience is came back during Lilly's rebuttal. Both sides also argued over a hypothetical from the briefs about a chocolate layer cake with non-chocolate layers.
Lilly also pressed an alternative argument. The statute gives FDA 60 days to answer a classification request, after which the sponsor's recommendation becomes the final determination. Lilly argues that once the district court vacated FDA's decision, the agency should be treated as having missed that deadline. FDA answers that it responded within 60 days and that the question is not properly before the court. At argument, Kedem said FDA still had not issued a decision on remand "more than nine months later."
What comes next
The supplemental memoranda are due October 8, 2026. If the court concludes it lacks jurisdiction, it would dismiss without reaching the protein question, and the case would continue at FDA on the analogous-product remand. If it keeps the case, it will decide the meaning of the definition. The Seventh Circuit sets no deadline for its decisions.
Update, October 14, 2026: FDA issued its remand decision on October 2, again finding that retatrutide is not a biological product, and both sides filed their jurisdiction memoranda on October 8. See FDA's October 2026 retatrutide decision.
Retatrutide is not approved in the United States. The classification determines which kind of application Lilly files for it and which pathway any future copies would take.
Where retatrutide sits in this index
As of September 28, 2026, retatrutide has 179 in-stock listings from 33 vendors in the PeptideScouter index, every vendor currently listing in-stock products, with a median of $4.87 per milligram. Definitions are on the methodology page.
The case concerns how FDA classifies Lilly's investigational product for approval. Nothing in the briefs, the district court opinion or the argument addresses products sold for research use.
Sources
- Seventh Circuit oral argument recording, No. 26-1301 (September 24, 2026), the source of all quotations from the argument.
- Seventh Circuit order directing supplemental memoranda (September 24, 2026), listing the panel and the October 8 deadline.
- Brief for Appellees, No. 26-1301 (May 15, 2026), FDA's brief, including the procedural history and the Mounjaro label point.
- Eli Lilly and Company v. Kennedy, No. 1:24-cv-01503 (S.D. Ind. September 30, 2025), the district court opinion, including Lilly's description of retatrutide's composition.
- CourtListener docket, No. 26-1301, the appellate docket.
- 21 C.F.R. 600.3, the regulatory definition of a protein at paragraph (h)(6).
- Federal Register, 85 FR 10057 (February 21, 2020), the final rule defining "biological product."
Listing and price figures are from the PeptideScouter index as of September 28, 2026, covering 33 vendors.